Alkem to launch state-of-the-art technology to treat DFU in India
Category: #tech  By Mateen Dalal  Date: 2022-01-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

Alkem to launch state-of-the-art technology to treat DFU in India

Alkem Laboratories Ltd. (Alkem), an Indian multinational pharmaceutical company, has reportedly launched a unique patented technology for the treatment of Diabetic Foot Ulcer (DFU) in India.

The solution would be based on an innovative technology of 4D Bioprinting, which would be used for treating non-healing, deep chronic wounds and is estimated to be launched in the second half of 2022 in the Indian market after receiving the regulatory approvals.

This cutting-edge technology for DFU management possesses high scope of averting amputations in diabetic patients. This technology will be obtainable at reasonable rates to the patients of India at a time when no decisive treatment of DFU is there in India.

At present, India has around 77 million diabetic patients, ranking it to be 2nd highest in the world. DFU (Diabetic foot ulcer) is one of the most common and disturbing complications of diabetes and is restricted as a foot affected by ulceration linked with neuropathy and peripheral arterial disease of the lower limb in a diabetic patient.

Moreover, around 12-15% of diabetic people suffer from DFU at least once in their whole lifetime. 5-24% of this population will finally lead to limb amputation within 6–18 months after the first assessment. The risks of getting limb amputation and foot ulceration increases in contrast to the age and duration of diabetes.

Imperatively, Alkem and Rokit Healthcare Inc. have collaborated to commercialize the technology in India to reduce amputation amongst DFU patients considering the adverse impact of amputation on the quality of patient’s life and the linked economic burden on the healthcare system.

Mr. Sandeep Singh, Managing Director, Alkem Laboratories Ltd., stated that diabetes is one of the major challenges faced by the healthcare systems in India. The challenge is so massive that diabetic foot ulcers get ignored very often. To address these issues, Alkem and Rokit Healthcare INC have collaborated to bring out a new solution for managing diabetic foot ulcers, Sandeep cited.

Source Credit - https://www.prnewswire.com/in/news-releases/alkem-laboratories-ltd-to-launch-state-of-the-art-technology-for-diabetic-foot-ulcer-management-for-the-first-time-in-india-838015097.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Microsoft investigates Teams and Outlook outage that left users disrupted
Microsoft investigates Teams and Outlook outage that left users disrupted
By Mateen Dalal

Microsoft, the U.S.-based technology frontrunner, reportedly investigating an outage that prevented thousands of customers from accessing services like Teams and Outlook. Apparently, the tech giant did not disclose the number of users that were im...

DeHaat secures $60 million in funding, tops $700 million valuation
DeHaat secures $60 million in funding, tops $700 million valuation
By Mateen Dalal

Indian agritech firm DeHaat has reportedly raised $60 million in a new funding round as it looks forward to strengthening its footprint in the country and touching break-even profitability in two years. For the unversed, the startup provides a range ...

Sensorium registers new branch in UAE to expand global presence
Sensorium registers new branch in UAE to expand global presence
By Mateen Dalal

Sensorium, developer of the Sensorium Galaxy metaverse, has registered its new branch in the United Arab Emirates (UAE) as Dubai gradually becomes a global hub for metaverse companies. The new entity, slated to be officially inaugurated in the com...